Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORT: Fosmetpantotenate in PKAN
NCT03041116Phase 3Terminated
- Sponsor
- Travere Therapeutics
- Start
- Jul 2017
- Primary completion
- Dec 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in pantothenate kinase-associated neurodegeneration (PKAN) comparing Fosmetpantotenate with Placebo (2 arms). Primary endpoints: Pantothenate Kinase-Associated Neurodegeneration-Activities of Daily Living at 24 weeks and Treatment-emergent Adverse Events and Serious Adverse Events at 24 weeks. Started Jul 2017; status: terminated.
02
Drugs
fosmetpantotenate
03
Conditions
pantothenate kinase-associated neurodegeneration (PKAN)
Beyond the preview
Go deeper on NCT03041116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041116.